The challenge is to assess changes assuming the worst possible outcome

August 2, 2022 Podcast

This is a preview of subscriber content

Subscribe now to continue reading.

The contentious 'catch-up' price reductions, the wording of industry agreements, the 'clever but consistent' policy approach, the real risk of other 'surprises' and the discomfort of having to defend federal government officials. …

Subscribe now to continue reading.

Latest Video

If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - Latest News
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - Latest News
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - Latest News
Australian company announces agreement with Lilly to trial lung cancer combination
August 4, 2026 - Latest News
The complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - Latest News

The challenge is to assess changes assuming the worst possible outcome

This is a preview of subscriber content

Latest Video

Most Read

If Australian companies shun their domestic market, who can blame multinationals?

The risk to patients is that new pricing policies could swamp any benefit from the HTA Review

Arrotex Pharmaceuticals appoints experienced industry executive as CMO

Australian company announces agreement with Lilly to trial lung cancer combination

The complete absence of patient power and agency makes this a health system outlier

New Stories

Injunction blocks generic launch of key HIV combination medicine

Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus

Neuren reports record DAYBUE sales as royalties rise and global expansion nears

NSW urged to think pharmacy first as 250 pharmacists near completion of advanced training

If Australian companies shun their domestic market, who can blame multinationals?

The complete absence of patient power and agency makes this a health system outlier

Pharmac announces plan to revise its recently expanded patient advisory function

Sign In

The challenge is to assess changes assuming the worst possible outcome

This is a preview of subscriber content

Latest Video

Most Read

If Australian companies shun their domestic market, who can blame multinationals?

The risk to patients is that new pricing policies could swamp any benefit from the HTA Review

Arrotex Pharmaceuticals appoints experienced industry executive as CMO

Australian company announces agreement with Lilly to trial lung cancer combination

The complete absence of patient power and agency makes this a health system outlier

Follow Us

New Stories

Injunction blocks generic launch of key HIV combination medicine

Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus

Neuren reports record DAYBUE sales as royalties rise and global expansion nears

NSW urged to think pharmacy first as 250 pharmacists near completion of advanced training

If Australian companies shun their domestic market, who can blame multinationals?

The complete absence of patient power and agency makes this a health system outlier

Pharmac announces plan to revise its recently expanded patient advisory function